Given periodic outbreaks of fatal human infections caused by coronaviruses, development of an optimal coronavirus vaccine platform capable of rapid production is an ongoing priority. This chapter describes the use of an insect cell expression system for rapid production of a recombinant vaccine against severe acute respiratory syndrome coronavirus (SARS). Detailed methods are presented for expression, purifi cation, and release testing of SARS recombinant spike protein antigen, followed by adjuvant formulation and animal testing. The methods herein described for rapid development of a highly protective SARS vaccine are equally suited to rapid development of vaccines against other fatal human coronavirus infections, e.g., the MERS coronavirus.
Introduction
The severe acute respiratory syndrome coronavirus (SARS) was fi rst identifi ed in 2003 after a series of fatal pneumonia cases characterized by an infl ammatory cell infi ltrate with diffuse alveolar damage [ 1 ] started in Hong Kong before spreading to other countries [ 2 ] . Before being controlled by quarantine measures, ~8000 humans were infected, with fatality as high as 50 % in the elderly and an overall case fatality rate of ~10 % [ 2 ] . More recently, the Middle East respiratory syndrome coronavirus (MERS) has caused a series of serious and, in some cases, fatal human infections [ 3 ] . Given the risk of future serious human coronavirus outbreaks, development of a suitable vaccine platform to protect against such viruses is a major priority. These vaccines present several challenges including the rapidity with which these outbreaks develop and hence the need for rapid vaccine manufacture. Hence, a successful coronavirus vaccine platform must overcome multiple challenges. SARS CoV is a positive-stranded RNA virus 29.7 kb in length with 14 open reading frames [ 4 ] . Initial SARS vaccine candidates were produced from inactivated virus. Inactivated whole-virus vaccines provided only modest protection, inducing low-neutralizing antibody titers that did not protect against infection but were associated with faster lung clearance of virus [ 5 ] . However, immunization of mice with inactivated vaccines either alone or formulated with alum adjuvant resulted in severe lung eosinophilic pathology in response to virus challenge [ 6 -9 ] , similar to enhanced lung pathology seen with SARS virus reexposure after primary infection [ 10 ] . Hence a major challenge when developing a SARS vaccine is to identify strategies to avoid lung eosinophilic pathology.
A further challenge when developing vaccines based on inactivated SARS virus is the need for high-containment biosafety level 3 cGMP manufacturing facilities [ 11 ] . This makes vaccine manufacture more complex and expensive and restricts the number of vaccine doses that can be rapidly manufactured. To counter these challenges, it would be preferable to produce a subunit vaccine that just like inactivated virus was able to induce neutralizing antibodies against SARS-CoV, but rather than requiring BSL3 manufacture was able to be produced in a regular recombinant protein manufacturing environment.
The potential solution to this problem lies in the coronavirus spike protein (S protein), which in the case of SARS virus binds to angiotensin-converting enzyme 2 and CD209L and induces receptor-mediated virus endocytosis, thereby being critical to virus entry into target cells [ 12 , 13 ] . S protein could thereby provide an ideal antigen with which to induce neutralizing antibodies against SARS virus [ 14 , 15 ] . However, while immunization with S protein in animal models provided some protection against SARS virus [ 16 , 17 ] , S protein-immunized animals when subsequently challenged with live virus developed severe lung eosinophilic immunopathology, with this problem exacerbated even further when S protein vaccine was formulated with alum adjuvant [ 6 , 9 ] . A similar problem of lung eosinophilic immunopathology has been seen with other viruses including respiratory syncytial virus (RSV) vaccines, which prime for an excessive and harmful Th2-dominated lung immune response upon subsequent virus exposure [ 18 ] . Lung eosinophilic immunopathology is exacerbated by formulation of such vaccines with any adjuvant that induces excess Th2 immune polarization, e.g., aluminum salt adjuvants [ 6 , 9 ] . Hence, while S protein would appear to be an ideal SARS vaccine antigen, there is fi rst the need to reduce the risk of lung eosinophilic immunopathology being induced by the vaccine.
Described below are methods used for the development and manufacture of a recombinant subunit vaccine based on an S protein antigen lacking transmembrane and cytoplasmic domains (S ΔTM) that was expressed using a baculovirus insect cell expression platform. As the S ΔTM protein antigen itself has low immunogenicity [ 16 , 17 ] , steps are also described for formulation with a safe and effective adjuvant [ 19 ] . As aluminum adjuvants are contraindicated for SARS vaccines given they may exacerbate lung eosinophilic pathology; instead methods are described for formulation of the S ΔTM protein with Advax™, a safe and effective adjuvant based on delta inulin [ 20 , 21 ] that has been previously shown in animal models to enhance the immunogenicity of a broad range of viral and bacterial antigens [ 22 -30 ] and has also been shown safe and effective in preliminary human clinical trials [ 31 , 32 ] . Notably, Advax adjuvant was recently shown to enhance the immunogenicity and protection conferred by both inactivated and recombinant SARS vaccines, without the excess Th2 bias of alum adjuvants and hence without the risk of inducing lung eosinophilic immunopathology [ 33 ] .
For this project a recombinant baculovirus was designed to express the ectodomain of the SARS S protein, lacking the transmembrane and cytoplasmic domains [ 17 ] . The recombinant protein expressed by this vector was termed SARS S ΔTM. This truncated version of the S protein was selected as it contains the receptor-binding domain (RBD) and was able to be expressed in insect cells at a higher level than the full-length membrane-bound version. The SARS S RBD has been shown to induce neutralizing antibodies against the SARS CoV [ 14 , 15 ] . After infection of expres SF+ ® insect cells with the recombinant baculovirus, the S ΔTM protein is expressed and secreted into the cell culture medium [ 17 ] . The procedure detailed below for purifying the SARS S ΔTM protein can be followed after production of the protein in a baculovirus/insect cell system. The process is designed for a 45 L fermentation in a 60 L bioreactor but may be adjusted to other scales as necessary. Following harvest, the SARS S ΔTM protein is purifi ed by column chromatography; a schematic is provided in Fig. 1 . In the fi rst step, the supernatant is fl owed through linked UNOsphere S (UNO S) and DEAE sepharose columns. DNA and protein impurities are removed, and the SARS S ΔTM protein remains in the fl ow through. The fl ow through from the UNO S/ DEAE step is applied to lentil lectin sepharose, SARS S ΔTM binds, and impurities are removed. Following elution from the lentil lectin sepharose column, the protein is concentrated, and buffer is exchanged by ultrafi ltration. The retentate from the ultrafi ltration step is processed through a 0.22 μm fi lter, and the purifi ed protein is stored at −20 °C. Prior to intended use, the purifi ed SARS S ΔTM protein is mixed under conditions with a suspension of Advax™ delta inulin adjuvant particles and either aseptically fi lled into single-dose vials or loaded directly into syringes ready for vaccination. Lastly, the adjuvanted SARS vaccine is tested for efficacy and safety in animal immunogenicity and SARS challenge models. 10. Sterile Nalgene square 500 mL polycarbonate bottle (Thermo Scientifi c). 2. Attach a process tank according to the manufacturer's instructions.
Fermentation in serum-free media

Fermentation Harvest
UNO S/DEAE
3. Fill process tank with water for injection (WFI).
4. Close permeate valve and circulate WFI through the system at 200 mL/min for 3-4 min.
5.
Open permeate valve.
6. Increase circulation rate to 600-800 mL/min. 
Lentil Lectin
Monitor volume of diafi ltration buffer in vessel.
24. Continue until a total volume of diafi ltration buffer equal to 10 times the volume of initial concentration retentate has been used.
25. Volume in process tank should be approximately equal to initial concentration retentate volume. This is the diafi ltration retentate.
26. Process the diafi ltration retentate through a 0.22 μm fi lter into a sterile Nalgene polycarbonate bottle. This is the S ΔTM bulk drug substance.
27. Remove aliquots for testing.
28. Store bulk drug substance at −20 °C.
1. Testing and acceptance criteria for SARS S ΔTM are listed in Table 1 . 1. Advax™ is a preservative-free sterile suspension of delta inulin microparticles at 50 mg/mL in a bicarbonate buffer, which when combined with vaccine antigen enhances both Th1 and Th2 immunity in a balanced fashion.
Antigen Release Testing
Vaccine Adjuvant Formulation
2. To further enhance Th1 and reduce Th2 immune bias, 10 μg CpG oligonucleotide per 1 mg delta inulin is added to the Advax™ adjuvant, as a simple admixture.
3. Advax™ adjuvant formulations are administered to mice at a standardized dose of 1 mg delta inulin per mouse, irrespective of the antigen dose.
4. Advax™ adjuvant is formulated with S ΔTM bulk drug substance in a laminar fl ow hood by aseptic simple admixture of the Advax™ suspension with the S ΔTM bulk drug substance and drawing up the combined milky white suspension into a 0.5 mL insulin syringe immediately prior to immunization.
1. Vaccine immunogenicity studies can be conveniently performed on adult female BALB/c mice at 6-8 weeks of age but can also be performed on other strains such as C57BL/6 ( see Note 6 ).
2. Mice are immunized twice 3 weeks apart by an intramuscular injection into the thigh, in order to mimic the most common route of human vaccine administration. The maximum volume that can be injected into an adult mouse thigh muscle is 50 μl.
If the vaccine cannot be reduced to this volume, then providing the vaccine is not reactogenic and then larger vaccine volumes can be administered by injection of 50 μl amounts into multiple legs.
3. Starting at 1 week post-immunization, at intervals of 1-4 weeks mice are bled using cheek vein bleeding using a lancet in order to obtain ~25-50 μl of blood from which serum is 6. For T cell proliferation assays, splenocytes are labeled with 5 μM CFSE (Invitrogen Life Technologies) for 8 min at RT. CFSE starts to react when exposed to aqueous solutions. It is, therefore, important to avoid dilution of CFSE until immediately before cell labeling. 2. To generate a mouse-adapted SARS -CoV, the SARS-CoV strain Urbani (200300592) was obtained from Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA). This strain was propagated and titrated in Vero 76 cells obtained from American Type Culture Collection (ATCC, Manassas, VA), and grown in minimal essential medium (MEM) supplemented with 10 % heat-inactivated fetal bovine serum (FBS, Thermo Fisher Scientifi c Co., Logan, UT). For in vitro antiviral assays, the serum was reduced to 2 % FBS and gentamicin was added to the medium up to a fi nal concentration of 50 μg/mL. BALB/c mice were infected with the Urbani strain. Three or fi ve days after infection, the lungs were removed and homogenized and then used to reinfect a subsequent group of mice. This infection step was continued 25 times through BALB/c mice lungs. The virus was then plaquepurifi ed three times and yielded a virus causing severe lung disease and mortality in infected mice. The virus was verifi ed as SARS-CoV by enzyme-linked immunosorbent assay ( ELISA ) and polymerase chain reaction (PCR). All experiments involving
Animal Immunogenicity Testing
SARS CoV Mouse Challenge Studies
infectious SARS-CoV viruses need to be conducted in an approved biosafety level 3+ laboratory.
3. At days 3 and 6 post-virus challenge, fi ve mice from each immunized and control group are sacrifi ced and the lungs harvested for gross pathology (lung score), lung weights, lung virus titers, and measurement of anti-SARS IgG in lung homogenate.
4. For lung scoring, samples from each mouse lung lobe are weighed and placed in a petri dish. Lungs are scored based on surface appearance of lungs. Lungs are then assigned a score ranging from 0 to 4, with 0 indicating that the lungs looked normal and 4 denoting that the entire surface area of the lungs was infl amed and exhibited plum-colored lung discoloration. 
7.
To assess for effects of vaccines on lung eosinophilic immunopathology, immunized and vehicle-treated mice are sacrifi ced at days 3 and 6 post-virus challenge, and lungs removed.
Formalin-fi xed lungs are mounted in paraffi n blocks. Paraffi nembedded lung sections are stained with hematoxylin and eosin (H&E) and a rat monoclonal antibody (Clone MT-14.7) to eosinophil major basic protein MBP (Lee Laboratory, Mayo Clinic, Arizona) following a standard IHC procedure. DAB chromogen identifi es eosinophils as brown-stained cells. Eosinophil infi ltration is scored without knowing animal identity using H&E-stained slides. An overall infi ltration score, 0-3, is assigned to each section according to the amounts of eosinophils in the parenchyma and their distributions through the lung. Score 0 = no to a few eosinophils; score 1 = mild eosinophil infi ltration; score 2 = moderate infi ltration; score 3 = severe infi ltration. For confi rmation, immunohistochemistry to the eosinophil major basic protein is performed in sections with the highest score of each treatment group. 
